Table 2 Incidence of individual cancer (per 1000 person-years) and estimated hazard ratios in the immune-mediated inflammatory diseases with colchicine compared to the immune-mediated inflammatory diseases without colchicine by Cox proportional hazard model with time-dependent covariates in propensity score-matched cohorts
Site of cancers | Colchicine | Crude HR (95% CI) | Adjusted HRb (95% CI) | |||
|---|---|---|---|---|---|---|
No (N = 16,026) | Yes (N = 16,026) | |||||
Event | Ratea | Event | Ratea | |||
Hematologic malignancy | 55 | 0.44 | 40 | 0.33 | 1.33 (0.60, 2.17) | 1.10 (0.58, 2.14) |
Head and neck cancer | 49 | 0.40 | 43 | 0.48 | 1.20 (0.92, 3.44) | 1.21 (0.85, 3.03) |
Esophagus | 23 | 0.19 | 18 | 0.15 | 0.78 (0.53, 3.55) | 1.00 (0.52, 3.63) |
Stomach | 50 | 0.40 | 41 | 0.43 | 1.05 (0.96, 3.97) | 1.17 (0.92, 3.77) |
Colorectal cancer | 170 | 1.37 | 39 | 0.27 | 0.20 (0.12, 0.97)* | 0.22 (0.19, 0.89)* |
Liver | 123 | 0.99 | 109 | 0.89 | 0.90 (0.78, 2.20) | 1.00 (0.85, 1.92) |
Pancreas | 21 | 0.17 | 16 | 0.13 | 0.76 (0.43, 5.12) | 0.89 (0.74, 4.70) |
Lung | 120 | 0.97 | 102 | 0.83 | 0.85 (0.80, 1.91) | 0.83 (0.76, 1.82) |
Skin | 19 | 0.15 | 17 | 0.14 | 0.93 (0.56, 4.09) | 0.74 (0.50, 4.30) |
Breast cancer | 70 | 1.13 | 56 | 0.98 | 0.87 (0.65, 2.05) | 0.86 (0.66, 2.67) |
Immune-related cancers | 174 | 1.41 | 141 | 1.15 | 0.82 (0.79, 1.69) | 0.83 (0.71, 1.52) |
Cervix | 17 | 0.28 | 16 | 0.28 | – | – |
Endometrium | 23 | 0.37 | 10 | 0.18 | – | – |
Ovary | 11 | 0.18 | 4 | 0.07 | 0.39 (0.18, 9.2) | 0.42 (0.21, 10.1) |
Prostate | 67 | 1.08 | 48 | 0.73 | 0.68 (0.50, 2.05) | 0.87 (0.67, 2.01) |
Bladder, kidney | 72 | 0.58 | 63 | 0.51 | 0.88 (0.55, 2.87) | 0.99 (0.90, 2.64) |
Brain | 4 | 0.03 | 2 | 0.02 | 0.66 (0.58,2.00) | 0.68 (0.42, 2.01) |
Thyroid | 21 | 0.17 | 16 | 0.13 | 0.76 (0.15, 2.56) | 0.80 (0.20, 3.56) |
Others | 43 | 0.35 | 32 | 0.26 | 0.74 (0.37, 2.03) | 0.81 (0.35, 1.99) |